spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  interleukin-6 

 HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 24 Jan 2017
FDA Grants Priority Review for Genentech’s Actemra(R) (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 4 Dec 2013
TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jan 2011
FDA Grants Supplemental Approval for ACTEMRA(R) (tocilizumab)
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jul 2010
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA(R) Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2010
Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Nov 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Biopharmaceuticals
 HSMN NewsFeed - 26 May 2009
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Lodotra(TM) Shows a Sustained Reduction of Morning Stiffness in Patients with Rheumatoid Arthritis Treated with Lodotra(TM) for 12 Months
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2007
Fourth ACTEMRA(TM) (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
Biopharmaceuticals
 HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
ACTEMRA(TM) (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2007
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 24 Jan 2007
Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate Significant Improvement in Signs and Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
New Study Shows ACTEMRA(TM) (tocilizumab) Significantly Improves Remission Rates in Patients with Rheumatoid Arthritis
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 2

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 2 additional stories matching:
interleukin-6
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!